Patents by Inventor Paolo Lusso

Paolo Lusso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210079070
    Abstract: Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.
    Type: Application
    Filed: February 21, 2019
    Publication date: March 18, 2021
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Paolo Lusso, Qingbo Liu, Peter Kwong, John Mascola, Young Do Kwon
  • Publication number: 20200399369
    Abstract: Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Application
    Filed: April 8, 2020
    Publication date: December 24, 2020
    Inventors: Mangaiarkarasi ASOKAN, Christian BEIL, Jochen BENINGA, Joerg BIRKENFELD, Mark CONNORS, Richard A. KOUP, Young Do KWON, Peter D. KWONG, Qingbo LIU, Paolo LUSSO, John R. MASCOLA, Gary J. NABEL, Amarendra PEGU, Huawei QIU, Ercole RAO, Joerg REGULA, Edward SEUNG, Ronnie WEI, Lan WU, Zhen XING, Ling XU, Zhi-Yong YANG, Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades
  • Patent number: 10808011
    Abstract: Embodiments of HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. Nucleic acid molecules encoding the HIV-1 Env ectodomain trimers are also provided. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: October 20, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Paolo Lusso, Peng Zhang
  • Publication number: 20190085032
    Abstract: Embodiments of HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. Nucleic acid molecules encoding the HIV-1 Env ectodomain trimers are also provided. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
    Type: Application
    Filed: March 9, 2017
    Publication date: March 21, 2019
    Applicant: The Unite States of America, as represented by the Secretary, Department of Health and Human Service
    Inventors: Paolo LUSSO, Peng ZHANG
  • Patent number: 9775895
    Abstract: HIV neutralizing peptides, sulfated HIV-1 envelope proteins and immunogenic fragments thereof are disclosed, as well as nucleic acids encoding these molecules and methods of producing these peptides, envelope proteins and fragments. Methods are also provided for the treatment or prevention of a human immunodeficiency type 1 (HIV-1 ) infection. The methods can include administering to a subject an HIV neutralizing peptide, sulfated HIV-1 envelope protein or immunogenic fragment thereof as disclosed herein. In several embodiments, administering the HIV neutralizing peptide, sulfated HIV-1 envelope protein or immunogenic fragment generates an immune response in a subject.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: October 3, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Paolo Lusso, Raffaello Cimbro
  • Publication number: 20150313990
    Abstract: HIV neutralizing peptides, sulfated HIV-1 envelope proteins and immunogenic fragments thereof are disclosed, as well as nucleic acids encoding these molecules and methods of producing these peptides, envelope proteins and fragments. Methods are also provided for the treatment or prevention of a human immunodeficiency type 1 (HIV-1) infection. The methods can include administering to a subject an HIV neutralizing peptide, sulfated HIV-1 envelope protein or immunogenic fragment thereof as disclosed herein. In several embodiments, administering the HIV neutralizing peptide, sulfated HIV-1 envelope protein or immunogenic fragment generates an immune response in a subject.
    Type: Application
    Filed: December 12, 2013
    Publication date: November 5, 2015
    Applicant: The USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Paolo Lusso, Raffaello Cimbro
  • Publication number: 20110236409
    Abstract: The present invention relates to set overlapping immunogenic peptides of a variable antigen, and uses thereof, in particular for diagnostic and therapeutic purposes. The present invention relates also to a sub-population of CD8 T cells associated with the non-progressive status in HIV-infected subjects.
    Type: Application
    Filed: March 30, 2009
    Publication date: September 29, 2011
    Applicant: Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
    Inventors: Mauro Severo Malnati, Paolo Lusso, Guido Poli, Antonio Cosma, Volker Erfle
  • Patent number: 8012719
    Abstract: Provided herein is a method for the quantitative detection of HHV-6 subtypes A and/or B based on the use of a calibrator, suitable primers and probes, and a nucleic acid polymerase with 5?-3? nuclease activity.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: September 6, 2011
    Inventors: Paolo Lusso, Mauro Malnati, Giulia Cassina
  • Patent number: 7968298
    Abstract: It has been discovered that herpesviruses can trigger an increase in the production of HIV-suppressive chemokines, and that these chemokines block the CCR5 receptor, which is used as a co-receptor with CD4 in the CCR5-tropic forms of HIV-1 that predominate in early stage HIV-1 infection. Use of live, attenuated or killed herpesviruses, or of herpesvirus proteins which trigger an increase in production of HIV-suppressive chemokines, or of nucleic acids encoding those proteins, can likewise be used to prevent establishment of HIV-1 infection or to inhibit HIV-1 replication. The invention provides uses, methods and compositions related to these discoveries.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: June 28, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Leonid B. Margolis, Jean-Charles Grivel, Paolo Lusso
  • Publication number: 20090029373
    Abstract: Provided herein is a method for the quantitative detection of HHV-6 subtypes A and/or B based on the use of a calibrator, suitable primers and probes, and a nucleic acid polymerase with 5?-3? nuclease activity.
    Type: Application
    Filed: June 5, 2008
    Publication date: January 29, 2009
    Inventors: Paolo LUSSO, Mauro Malnati, Giulia Cassina
  • Patent number: 7384769
    Abstract: Provided herein is a method for the quantitative detection of nucleic acids based on the use of a calibrator, suitable primers and probes, and a nucleic acid polymerase with 5?-3? nuclease activity.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: June 10, 2008
    Inventors: Giuseppe Locatelli, Paolo Lusso, Mauro Malnati, Francesca Salvatori, Gabriella Scarlatti
  • Patent number: 7164000
    Abstract: RANTES mutants characterised by the substitution or addition of amino acids at the N-terminal of RANTES wild-type sequence and in the N-loop and/or 40's loop regions of RANTES wild-type sequence, and their use as anti-HIV, anti-allergic or anti-inflammatory agents.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: January 16, 2007
    Assignee: Fondazione Centro San Raffaele Del Monte Tabor
    Inventors: Paolo Lusso, Simona Polo
  • Publication number: 20060165650
    Abstract: RANTES-derived peptides and the use thereof in the treatment of diseases in which RANTES receptor is involved, such as viral infections, particularly HIV infections, and inflammatory, allergic, degenerative, neoplastic or metastatic diseases.
    Type: Application
    Filed: January 22, 2004
    Publication date: July 27, 2006
    Inventors: Vincenzo Pavone, Paolo Lusso
  • Publication number: 20060142219
    Abstract: Pharmaceutical composition for treating/preventing HIV comprising (i) a polynucleotide encoding HIV envelope protein and (ii) a polynucleotide encoding CD4 receptor protein or; (i) a polynucleotide encoding HIV envelope protein and (ii) a CD4 receptor protein or; a fixed cell expressing an HIV envelope protein complexed with a CD4 receptor protein. Also disclosed are pharmaceutical compositions for treating/preventing HIV comprising an antibody immunospecific for a fixed cell expressing an HIV envelope protein complex with a CD4 receptor protein. The binding of the CD4 to the HIV envelope protein, i.e. gp120, exposes hidden epitopes that may be used as targets in immunotherapy; the presentation of the gp120 and CD4 in the present forms is said to overcome problems with prior art soluble gp120-CD4 complexes.
    Type: Application
    Filed: August 12, 2003
    Publication date: June 29, 2006
    Inventors: Paolo Lusso, Samuele Burastero
  • Patent number: 7029843
    Abstract: Provided herein is a method for the quantitative detection of nucleic acids based on the use of a calibrator, suitable primers and probes, and a nucleic acid polymerase with 5?-3? nuclease activity.
    Type: Grant
    Filed: November 17, 1999
    Date of Patent: April 18, 2006
    Assignee: Fondazione Centro San Raffaele Del Monte Tabor
    Inventors: Giuseppe Locatelli, Paolo Lusso, Mauro Malnati, Francesca Salvatori, Gabriella Scarlatti
  • Publication number: 20050239128
    Abstract: Provided herein is a method for the quantitative detection of nucleic acids based on the use of a calibrator, suitable primers and probes, and a nucleic acid polymerase with 5?-3? nuclease activity.
    Type: Application
    Filed: June 30, 2005
    Publication date: October 27, 2005
    Inventors: Giuseppe Locatelli, Paolo Lusso, Mauro Malnati, Francesca Salvatori, Gabriella Scarlatti
  • Publication number: 20050123510
    Abstract: It has been discovered that herpesviruses can trigger an increase in the production of HIV-suppressive chemokines, and that these chemokines block the CCR5 receptor, which is used as a co-receptor with CD4 in the CCR5-tropic forms of HIV-1 that predominate in early stage HIV-1 infection. Use of live, attenuated or killed herpesviruses, or of herpesvirus proteins which trigger an increase in production of HIV-suppressive chemokines, or of nucleic acids encoding those proteins, can likewise be used to prevent establishment of HIV-1 infection or to inhibit HIV-1 replication. The invention provides uses, methods and compositions related to these discoveries.
    Type: Application
    Filed: March 28, 2002
    Publication date: June 9, 2005
    Applicant: The Government of the United States, as represent- ed by the Secretary of Health and Human Services,
    Inventors: Leonid Margolis, Jean-Charles Grivel, Paolo Lusso
  • Patent number: 6709649
    Abstract: Peptides having 12 to 30 amino acids with sequence homologous or corresponding to the sequence 1o-34 of RANTES having inhibitory activity against the human immunodeficiency virus (HIV) as well as anti-allergic and antiinflamatory activity.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: March 23, 2004
    Assignees: Fondazione Centro San Raffaele Del Monte Tabor, PRIMM S.r.l.
    Inventors: Paolo Lusso, Vincenzo Pavone
  • Publication number: 20030216549
    Abstract: RANTES mutants characterised by the substitution or addition of amino acids at the N-terminal of RANTES wild-type sequence and in the N-loop and/or 40's loop regions of RANTES wild-type sequence, and their use as anti-HIV, anti-allergic or anti-inflammatory agents.
    Type: Application
    Filed: March 28, 2003
    Publication date: November 20, 2003
    Applicant: FONDAZIONE CENTRO SAN RAFFAELLE DEL MONTE TABOR
    Inventors: Paolo Lusso, Simona Polo
  • Patent number: 6608177
    Abstract: RANTES mutants characterized by the substitution or addition of amino acids at the N-terminal or RANTES wild-type sequence and in the N loop and/or 40′ loop regions of RNATES wild-type sequence, and their use as anti-HIV, anti-allergic or anti-inflammatory agents.
    Type: Grant
    Filed: June 9, 2000
    Date of Patent: August 19, 2003
    Assignee: Fondazione Centro San Raffaele del Monte Tabor
    Inventors: Paolo Lusso, Simona Polo